How can customers be made loyal to a fuel-brand :creating loyalty through gamification, urban INTRODUCTION: The Greek philosopher Plato once said you could learn more about a man in one hour of play than in a whole year of conversation. Plato was on to something. It turns out that you can not only learn more about people while they play, but that you can also enhanc
sydneyrx2014.com Online ED Drugstore is an 1st. pharmacy providing a personal service to the society in Australia. Over 50,000 extremely satisfied buyers! We're your prescription drug store levitra australia and have provided trusted service to families in Australia for over 15 years.
Microsoft word - case90_health_beyond_medicine_enHealth beyond Medicine
This article introduces a creative approach to health management as one of the 100 innovations that shape "The Blue Economy". This article is part of a broad effort to stimulate entrepreneurship, competitiveness and employment.
The world market for antibiotics is expected to grow worldwide from $26 billion in 2002 to
$40.3 billion by 2015. The growth is expected to be strong, in spite of the fact that the
industry has lately been incapable of discovering completely new antibiotics. It is rather a
favorable regulatory environment where government insurance programs are prepared to
pay more for drugs in the wake of a widespread awareness of antibiotics resistance, and the
reemergence of once considered controlled illnesses like tuberculosis. The United States is
the largest market in the world for antibiotics where the consumption of this type of
prescription drugs has increased fourfold over just one decade.
Antibiotics were first discovered when Alexander Fleming in 1929 by accident learned how
penicillin controls bacteria. Fleming never patented penicillin, and offered it open source to
the medical community and society. That earned him the Nobel Prize for Medicine in 1945.
Surprisingly, the largest growth market for antibiotics today is not for the protection of human
health. It is estimated that 50 to 70 percent of antibiotics are delivered to healthy animals to
boost their growth by 2 to 3 percent, instead of being administered to sick people. While the
European Union recently banned most uses of antibiotics for animals, countries like Denmark
pioneered this policy with a ban as early as 2000. After one decade, statistics indicate that
bacterial resistance to antibiotics is decreasing.
The number of new antibiotics is extremely low. Just five of the thirteen largest
pharmaceutical firms try to discover new antibiotics. Only five new variations of existing
antibiotics were approved between 2003 and 2007 by the FDA down from 16 twenty years
earlier. The problem is that antibiotics are only administered one or two weeks to cure a
patient, whereas a cancer or a diabetes patient might have to take drugs for life, thus
representing a more profitable market. At the same time mutations in E.coli have left specific
strains of this germ completely invulnerable to nearly all modern antibiotics. About 100,000
Americans now contract illnesses in hospitals each year.
The Methicillin-resistant Staphylococcus aureus (MRSA), a mutated bacterial strain now kills
more Americans than AIDS. It is clear that technology and the market has failed. As the
patent on an antibiotic expires, it is sold as a generic drug at a fraction of the original price,
leading to an increased consumption contributing to further mutations and bacterial
resistance. At the same time, the expiration of the patent leads to a drop in revenues which
implies that the lower returns eliminate the budget for research and development. In the end,
the build-up of resistance to that particular antibiotic does not get monitored by the inventor,
the former patent holder or the generic drugs manufacturer.
Scientists warn that everyday infections could soon become again a major cause of death.
While the notion of subsidizing drug development at a rate of one billion dollars per drug, and
guaranteeing coverage to patients seems to be a costly avenue, many wonder how to bridge
the gap between the urgency for new antibiotics in society and the low returns – in spite of
the massive subsidies – antibiotics’ sales through government health schemes provide to
drug companies. Experts urge that policies should be introduced on conserving the
effectiveness of existing drugs by preventing excessive use in medical care and animal
husbandry, while ensuring better infection controls in hospitals. The innovative thinking goes
along the line that antibiotics are like biodiversity, it is a natural resource that should be
preserved and used with great care.
James Colthurst, a British surgeon and the great grandson of Sir Almroth Wright inventor of
the typhoid vaccine, who worked in the same lab as Alexander Fleming, had been studying
electrical effects on the body ever since his sister was badly head-injured. Because he was
known to be involved in this field, he was approached by a group of USSR scientists working,
who were exploring an electrical stimulation concept as a futuristic tool for health care in
space travel. He helped to develop their equipment for wider use. Once perestroika occurred,
and they chose to market what they had, Dr. Colthurst sought to develop his own ideas of
electro-biofeedback. On the back of the work he had undertaken during his Bachelor’s of
Science degree studying neuro-anatomy at St. Thomas’ Hospital in 1978, he designed the
This hypothesis is based on the fact that the nerves arise from the same embryonic layer as
the skin – the neuroectoderm. A network of nerves, both central, the central nervous system
(CNS) comprising the brain, the spinal cord and the peripheral nervous system (PNS),
collect, integrate and disseminate information around the body via electrical impulses. These
impulses are converted to chemical messengers guiding cell activity. The electric stimulation
through a simple device meeting all European Union and United States FDA regulations is
akin to nerve impulses shaping a biofeedback process through simple contact with the skin
engaging in a dialogue with the CNS. Soon, Dr. Colthurst and his team could gather
anecdotal evidence ranging from treating asthma to wound healing, recovery from Bell's
palsy (loss of control of the muscle movements in the face), to treating Crohn's disease and
Systemic Lupus. The case whereby pharmaceuticals and surgery could be replaced by no
drugs or operation is one of the characteristics of The Blue Economy simplified under the
concept "replace something with nothing".
The First Cash Flow
Following a retrospective audit of 600 patients which was published in the Pain Clinic (The
Pain Clinic, 2007 Vol. 19 No. 1) an initial pilot study on the use of electrical stimulation based
on the Fenzian in asthma was published in a letter in the European Respiratory Journal in
2009 (Vol. 34 No. 2 pages 515-517). This showed proof of concept of a novel treatment
without relying on pharmaceuticals. Whereas the scientists agree that the exact mechanism
remains unknown they agreed that biofeedback could induce changes through the CNS. This
lead to the set up of clinical trials in six medical centers including UCLA, Johns Hopkins
Hospital and the University of Cape Town. At the same time funding has been made
available for extended studies at the Manchester Interdisciplinary Biocentre. The scientific
and wound research from Manchester continues to deliver extremely positive results. A
number of in vitro studies are now needed to underpin the in vivo work in order to prove the
scientific pathway. In the mean time Dr. Colthurst created Fenzian Limited, a privately owned
UK registered medical research and development company with the support of European
investors who have enjoyed different degrees of positive experiences with the Fenzian
approach to medicine and health care.
Governments face multiple challenges. On one hand the greying of the population implies
ever increasing costs for health care. Then, governments are facing a growing budget deficit,
and subsidization at the rate of billions is increasingly difficult for any government department
to approve. Pharmaceutical companies are on the other hand facing an ever higher burden
to get new medicine approved, litigation costs are climbing, many drugs are at the end of
their patent life, and counterfeit medication is a growing problem, while surgery and an
extended stay in a hospital exposes patients to potential infections. The wide spectrum of
potential applications of Dr. Colthurst's pioneering approach with the Fenzian technology
provides a fresh look that frees pharmaceutical enterprises to focus on a pharmacological
chemistry only. Fenzian cuts the need for subsidies, reduces costs of side-effects and works
with the inherent capacity of the body to heal itself. Use what you have, is one of the core
principles of The Blue Economy.
…………………………………………………………………………………………………………… Further information on the 100 innovations at www.blueeconomy.eu. Order Gunter Paulis book at www.blueeconomy.eu: Zen and the Art of Blue
Publication and dissemination of this article, including translations, require prior written consent.
Please contact <firstname.lastname@example.org>. …………………………………………………………………………………………………………… The Blue Economy | All rights reserved. 2010, Pauli
Schuyler W. Henderson, M.D., Michael S. Jellinek, M.D. Prelude to a School Shooting? Assessing ThreateningOn March 21, 2005, Jeffrey Weise, a 16-year-old student at Red Lake16, 2007, the deadliest school shooting in U.S. historyHigh School, Minnesota, killed his grandfather and his grandfather_soccurred at Virginia Tech when a student, Seung-Huigirlfriend. Next, he drove his grandfather_s sq